Skip to content

Author

I. Hilgendorf

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation

Timing of vaccination influenced immune response, with a stronger response after the 3rd dose compared to the initial series, and patients vaccinated within 24 months of alloHSCT had significantly lower anti-spike IgG levels than those vaccinated later.

C. Crodel, Laura Gork, W. Göpel et al. · 0 citations
Open access Aug 2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.

A. O. Saidy, B. Altmann, P. van Heteren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.